[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-393880-105":59,"doc-detail-393880-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","overweight-obesity-and-contraception-april-2019","Overweight, Obesity and Contraception - April 2019","","FSRH guideline published in April 2019 covering contraception for women with overweight or obesity. It explains definitions of overweight and obesity, the rationale for linking contraception with raised BMI, and summarizes evidence on fertility, sexual activity, contraceptive use, and unintended pregnancy. It grades recommendations using an evidence classification framework and provides detailed sections on suitability and effectiveness, safety, weight gain, health benefits, and practical considerations for long-acting reversible contraception and progestogen-only options.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/overweight-obesity-and-contraception-april-2019/393880/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/overweight-obesity-and-contraception-april-2019/393880.png","ImageObject",300,407,{"name":92,"@type":93},"Aran","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-26",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",14,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What is the purpose and scope of the FSRH guideline on overweight, obesity and contraception (April 2019)?","Question",{"text":113,"@type":114},"It sets out recommendations for contraception suitability for women who are overweight or have obesity, focusing on the need for contraceptive options in relation to raised BMI and summarizing relevant evidence.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How does the guideline define overweight and obesity and connect this to contraception decisions?",{"text":118,"@type":114},"It includes dedicated sections defining overweight and obesity and explains why the guideline specifically focuses on contraception and raised BMI, linking these concepts to evidence on fertility, sexual activity, contraceptive use, and unintended pregnancy.",{"name":120,"@type":111,"acceptedAnswer":121},"Which contraceptive methods are covered for women with raised BMI?",{"text":122,"@type":114},"The guideline addresses suitability across several progestogen-only and intrauterine options, including intrauterine contraception (IUC), progestogen-only implants (IMP), progestogen-only injectable, and progestogen-only pill (POP).","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},393880,1790532929,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":21,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},137455076865,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","FSRH Guideline  \nOverweight, Obesity & Contraception  \nApril 2019 | FSRH  \nFaculty of Sexual & Reproductive Healthcare (FSRH) provided funding to the Clinical Effectiveness Unit (of the FSRH) to assist them in the production of this guideline,  \nOverweight, Obesity and Contraception (April 2019) .  \nPublished by the Faculty of Sexual & Reproductive Healthcare.  \nRegistered in England No. 2804213 and Registered Charity No. 1019969.  \nCopyright © Faculty of Sexual & Reproductive Healthcare, April 2019.  \nPermission is granted to reproduce or transmit this document for non-commercial personal and non-commercial education use only. Commercial use of any kind, including copying, hiring and  \nlending, is prohibited.  \nAny reproduction of the whole of this document must reproduce this copyright notice in its entirety.  \nAny reproduction of a part of this document must include a statement that it is reproduced under licence from FSRH and the notice Copyright © Faculty of Sexual & Reproductive Healthcare,  \nApril 2019.  \nPublished in the UK.  \nNICE has accredited the process used by the Faculty of Sexual & Reproductive Healthcare to produce this guideline. More information on accreditation can be viewed [at www.nice.org.uk/](at www.nice.org.uk/)  \n[accreditation.](accreditation.)  \nFrom January 2019 the FSRH has published its electronic clinical guidelines on both its own website ([www.fsrh.org.uk](www.fsrh.org.uk)) and as an electronic supplement to the BMJ Sexual & Reproductive Health (BMJSRH) journal. The guidelines have the same content. If a guideline is updated, the FSRH replace the version on its website and the BMJ Sexual & Reproductive Health (BMJ SRH) journal will ensure old versions of guidelines will clearly signpost the newer version.  \nAbbreviations used  \nBMD  \nBMI  \nCEU  \nCHC  \nCI  \nCOC  \nCu-IUD  \nCVD  \nDMPA  \nDSG  \nEC  \nEE  \nENG  \nFSRH  \nGDG  \nHCP  \nHFI  \nHMB  \nHR  \nIMP  \nIUC  \nLARC  \nLNG  \nLNG-EC  \nLNG-IUS  \nMI  \nNET-EN  \nNGMN  \nOC  \nOR  \nPOP  \nRCT  \nSPC  \nUKMEC  \nUPA  \nUPA-EC  \nVTE  \nWHO  \nbone mineral density  \nbody mass index  \nClinical Effectiveness Unit  \ncombined hormonal contraception/contraceptive confidence interval  \ncombined oral contraception/contraceptive copper intrauterine device  \ncardiovascular disease  \ndepot medroxyprogesterone acetate desogestrel  \nemergency contraception  \nethinylestradiol  \netonogestrel  \nFaculty of Sexual & Reproductive Healthcare guideline development group  \nhealthcare practitioner  \nhormone-free interval  \nheavy menstrual bleeding  \nhazard ratio  \nprogestogen-only implant  \nintrauterine contraception/contraceptive  \nlong-acting reversible contraception/contraceptive levonorgestrel  \nlevonorgestrel (for emergency contraception) levonorgestrel-releasing intrauterine system myocardial infarction  \nnorethisterone enanthate  \nnorelgestromin  \noral contraception/contraceptive  \nodds ratio  \nprogestogen-only pill  \nrandomised controlled trial  \nSummary of Product Characteristics  \nUK Medical Eligibility for Contraceptive Use ulipristal acetate  \nulipristal acetate (for emergency contraception) venous thromboembolism  \nWorld Health Organization  \nGrading of recommendations  \n\n| Refer to Appendix 1 for a full explanation of the classification of evidence level and grading of recommendations. |  |\n| --- | --- |\n| A\u003Cbr>| At least one meta-analysis, systematic review or randomised controlled trial (RCT) rated as 1++, and directly applicable to the target population;\u003Cbr>or\u003Cbr>A systematic review of RCTs or a body of evidence consisting principally of studies rated as 1+, directly applicable to the target population and demonstrating overall consistency of results. |\n|  | A body of evidence including studies rated as 2++ directly applicable to the target population |\n| B\u003Cbr>| and demonstrating overall consistency of results;\u003Cbr>or\u003Cbr>Extrapolated evidence from studies rated as 1++ or 1+ . |\n|  | A body of evidence including studies rated as 2+ directly applicable to the target population |","cbCaitPqdTOxOITC","https://ap.wps.com/l/cbCaitPqdTOxOITC","pdf",875076,"English","# Executive summary of recommendations\n# 1 Purpose and scope\n# 2 Definitions of overweight and obesity\n# 3 Why this guideline focuses on contraception and raised BMI\n# 4 Overview of evidence on fertility and unintended pregnancy\n# 5 Suitability of contraceptive methods for women with raised BMI\n## 5.1 Intrauterine contraception (IUC)\n## 5.2 Progestogen-only implants (IMP)\n## 5.3 Progestogen-only injectable\n## 5.4 Progestogen-only pill (POP)","[{\"question\":\"What is the purpose and scope of the FSRH guideline on overweight, obesity and contraception (April 2019)?\",\"answer\":\"It sets out recommendations for contraception suitability for women who are overweight or have obesity, focusing on the need for contraceptive options in relation to raised BMI and summarizing relevant evidence.\"},{\"question\":\"How does the guideline define overweight and obesity and connect this to contraception decisions?\",\"answer\":\"It includes dedicated sections defining overweight and obesity and explains why the guideline specifically focuses on contraception and raised BMI, linking these concepts to evidence on fertility, sexual activity, contraceptive use, and unintended pregnancy.\"},{\"question\":\"Which contraceptive methods are covered for women with raised BMI?\",\"answer\":\"The guideline addresses suitability across several progestogen-only and intrauterine options, including intrauterine contraception (IUC), progestogen-only implants (IMP), progestogen-only injectable, and progestogen-only pill (POP).\"}]","Overweight, Obesity and Contraception - April 2019 | PDF",1790395347,176]